Long‐term outcome of high‐grade encapsulated papillary carcinoma of the breast: implications for staging and management
Open Access
- 3 August 2026
- journal article
- Published by Wiley in Histopathology
- Vol. 89 (6) , 941-953
Abstract
Background: Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC‐A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high‐grade EPC (HG‐EPC), including EPC‐A. Materials and methods: This retrospective multicentre study (2000–2025) included 25 HG‐EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re‐evaluation was performed in accordance with 2019 WHO classification criteria. Results: Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional‐type microinvasive components. A subset of 16 cases fulfilled criteria for EPC‐A, defined by high‐grade morphology in combination with ER/PR‐negative (or ER n = 13) to pT1 ( n = 4) or pT2 ( n = 7), and pT3 ( n = 1). Adjuvant chemotherapy and radiotherapy were administered in 7 and 12 patients respectively. During follow‐up, four local recurrences (three invasive and one in situ ) were observed. One of the locally recurrent patients subsequently developed distant metastasis, and one breast cancer‐related death occurred 200 months after diagnosis. Recurrence or death occurred in 20% (5/25) of patients despite therapy. Microinvasion was seen only in the EPC‐A tumours. Conclusion: HG‐EPC and EPC‐A overlap morphologically and diagnostically with frankly invasive carcinomas and demonstrate a non‐negligible risk of recurrence. Clinical outcomes and more frequent microinvasion in EPC‐A support the view that EPC‐A is more appropriately regarded as an indolent form of invasive carcinoma rather than a purely in situ lesion and demonstrate a non‐negligible risk of recurrence and highlight the need for standardized staging criteria.Keywords
This publication has 30 references indexed in Scilit:
- Biological behavior of DCIS with or without microinvasion. Same and differentHuman Pathology, 2025
- Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatmentThe Lancet, 2024
- Encapsulated papillary carcinoma of the breast: An institutional case series and literature reviewCancer Medicine, 2023
- Breast Cancer: From Bench to Personalized Medicine2022
- Papillary neoplasms of the breast—reviewing the spectrumLaboratory Investigation, 2021
- Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomesBreast Cancer Research and Treatment, 2020
- Epidemiology of Breast Cancer in Women2019
- Encapsulated papillary carcinoma of the breast: A clinicopathological study of 49 casesCurrent Problems in Cancer, 2018
- Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgeryThe Lancet Oncology, 2013
- Treatment and outcome of patients with intracystic papillary carcinoma of the breastThe American Journal of Surgery, 2002